Advanced search×

RNA from Borna disease virus in patients with schizophrenia, schizoaffective patients, and in their biological relatives.

J Clin Lab Anal 22(4):314-20 (2008) PMID 18623121

Numerous interactions of the immune system with the central nervous system have been described recently. Mood and psychotic disorders, such as severe depression and schizophrenia, are both heterogeneous disorders regarding clinical symptomatology, the acuity of symptoms, the clinical course, the treatment response, and probably also the etiology. Detection of p24 RNA from Borna disease virus (BDV) by the reverse transcriptase polymerase chain reaction in patients with schizophrenia, schizoaffective disorder, and in their biological relatives was evaluated. The subjects were 27 schizophrenic and schizoaffective patients, 27 healthy controls, 20 relatives without psychiatric disease, and 24 relatives with mood disorder, who attended the Psychiatric Ambulatory of Londrina State University, ParanĂ¡, Brazil. The subjects were interviewed by structured diagnostic criteria categorized according to the Diagnostic and Statistical Manual of Mental Disorders-IV, axis I, (SCID-IV). The mean duration of illness in schizophrenic and schizoaffective patients was 15.341+/-1.494 years and the median age at onset was 22.4+/-7.371 years. There were no significant differences in gender (P=0.297), age (P=0.99), albumin (P=0.26), and body mass index (kg/m(2)) (p=0.28), among patients, controls, and relatives. Patients and biological relatives had significantly higher positive p24 RNA BDV detection than controls (P=0.04); however, the clinical significance of BDV remains to be clarified.

DOI: 10.1002/jcla.20261
Version: za2963e q8zaa q8zb5 q8zca q8zdf q8zef q8zf3 q8zg7

Similar articles you may find interesting…

  1. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting.

    Ther Adv Respir Dis (2013) PMID 23653458

    The cost of COPD may vary according to compliance with the GOLD guidelines. The cost observed for patients with stage II disease is higher than expected in patients who adhere to treatment, but patients with stage III disease treated according to the GOLD guidelines had significantly higher treatmen...
  2. Clinical and Molecular Characterization of Mcardle's Disease in Brazilian Patients.

    Neuromolecular Med (2013) PMID 23653251

    We describe the clinical phenotype and genotype of 10 patients from 8 unrelated Brazilian families. Among the 10 patients (3 females, 7 males), eight presented with the typical phenotype, with exercise intolerance, cramps, and myalgia; one patient showed permanent muscle weakness; and one patient sh...
  3. Management of sialorrhoea in motor neuron disease: A survey of current UK practice.

    Amyotrophic Lateral Sclerosis and Frontotemporal De... (2013) PMID 23647474

    We used a survey of neurologists in the UK with a special interest in motor neuron disease designed to establish clinicians' attitudes towards treatment options and resources for sialorrhoea management. Twenty-three clinicians replied, representing 21 centres. Sixteen centres were specialist MND Car...